Pill with electronic patient-compliance sensor inside approved in US

FDA approves pill with digital tracking device you swallow

FDA approves pill with digital tracking device you swallow

USA regulators have approved the first pill that can be digitally tracked through the body.

The Abilify MyCite aripiprazole tablets - for treating schizophrenia and manic episodes - have an ingestible sensor embedded inside them that records that the medication has been taken, and a patch worn by the patient transmits this information to their smart phone.

The prescribing notes also stress that Abilify MyCite should not be used to track drug ingestion in "real-time" or during an emergency, because detection may be delayed or may not occur.

Patients can give permission to their doctors and up to four other people, such as carers or family members, to receive electronic data showing the time and date the pills are ingested.

The drug was made in collaboration with Otsuka Pharmaceutical and Proteus Digital Health, which designed the sensor.

"The FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers".

The U.S. Food and Drug Administration (FDA) has reportedly approved a pill that is endowed with a unique digital tracking device.

Makers of the pill said initially the drug would only be used in a small number of patients in the United States, to track the patients' experience with the medication.

Andrew Thompson, president and CEO at Proteus Digital Health, said: "The time is right for the category of Digital Medicines to be available to appropriate patients with serious mental illness".

"This technology can help enable individuals with serious mental illness to engage with their care team about their treatment plan in a new way".

Notícias recomendadas

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.